Related Experiment Videos
Reversible cardiomyopathy after high-dose interleukin-2 therapy
1Department of Internal Medicine, Wayne State University School of Medicine, Harper Hospital, Detroit, Michigan 48201.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|April 1, 1992
Summary
High-dose interleukin-2 (IL-2) therapy can cause asymptomatic myocardial injury. This cardiac dysfunction is reversible, but may persist for over four weeks in some patients.
Area of Science:
- Cardiology
- Immunology
- Oncology
Background:
- High-dose interleukin-2 (IL-2) is used in cancer immunotherapy.
- Potential cardiac side effects of IL-2 therapy require careful monitoring.
Observation:
- Two patients receiving high-dose IL-2 developed moderate global myocardial dysfunction.
- Elevated cardiac enzymes were noted, but without ischemic symptoms.
- Echocardiography confirmed myocardial dysfunction, with variable recovery times.
Findings:
- Asymptomatic, reversible myocardial injury is a potential complication of high-dose IL-2.
- Recovery from IL-2-induced cardiac dysfunction can extend beyond four weeks.
- Literature suggests IL-2-associated myocarditis as a likely cause.
Implications:
- Clinicians should be aware of potential cardiac toxicity with high-dose IL-2.
- Serial cardiac monitoring may be necessary for patients undergoing IL-2 therapy.
- Further research into IL-2-associated myocarditis is warranted.